|
KMID : 0978920120130010003
|
|
Korean Journal of Clinical Geriatrics
2012 Volume.13 No. 1 p.3 ~ p.3
|
|
|
Safety and Efficacy of Adjunctive Cilostazol in Patients with Old Age (≥75 years)
|
|
Rha Seung-Woon
Poddar Kanhaiya L.
Park Ji-Young
Choi Byoung-Geol
Choi Se-Yeon
Na Jin-Oh
Choi Cheol-Ung
Lim Hong-Euy
Kim Jin-Won
Han Sung-Woo
Kim Eung-Ju
Park Chang-Gyu
Seo Hong-Seog
Oh Dong-Joo
|
|
|
Abstract
|
|
|
Background: Adjunctive Cilostazol (Pletaalⓡ) to dual antiplatelet therapy (triple antiplatelet) is known to improve
outcomes after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Very old age (≥75 years) can
be a worse prognostic factor after PCI and safety of triple antiplatelet therapy is not elucidated yet.
Methods: The study population consisted of 307 consecutive pts ≥ 75 years of age and underwent PCI with DES
from April 2006 to February 2009. Cilostazol was administered by 200 mg post-loading and then 100 mg bid for
at least one month. Clinical and angiographic outcomes up to 6 months of triple group were compared with those
of dual antiplatelet group.
Results: Out of 307 patients treated with PCI with DES, 115 pts received adjunctive Cilostazol whereas 192 pts received dual antiplatelet therapy. Cilostazol group had more diffuse long lesions (40.9% vs. 27.6%; P=0.03). There was no
difference in major bleeding and vascular complications between the two groups. At 6 months, multivariate logistic
analysis showed no significant difference in major clinical and angiographic outcomes (Table 1).
Conclusion: Pts with very old age (≥75 years) who receive adjunctive Cilostazol after PCI with DES appears
to be similarly safe and effective in reducing midterm clinical and angiographic events compared with those of
dual antiplatelet group.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|